MS Research Studies

This study is being done to see how effective and tolerable ublituximab is when given to people who had been receiving different anti-CD20 therapy for relapsing multiple sclerosis. Ublituximab is approved by the US Food and Drug Administration (FDA) with the name BRIUMVI®, for adults with relapsing forms of multiple sclerosis.

What is this study about?

This clinical trial is testing a potential new treatment called nasal foralumab, a type of

antibody therapy, to see if it can help slow disease progression in people with non-active

secondary progressive multiple sclerosis (SPMS).

Who can participate?

You may be eligible if you:

• Are between 18 and 75 years old
• Have a confirmed diagnosis of non-active SPMS for at least 2 years prior to screening
• Have experienced worsening symptoms despite standard MS treatments
• Meet other health and imaging criteria

What does participation involve?

• You’ll be randomly assigned to receive either nasal foralumab (at one of two doses) or placebo
• Treatment is given 3 times a week for 2 weeks, followed by 1 week off, repeated over 4 cycles (12 weeks total).
• The study includes PET scans to monitor brain inflammation and other health assessments.

Why participate?

By joining, you’ll help researchers learn whether nasal foralumab can safely reduce

inflammation and slow disability progression in non-active SPMS. Your participation could

contribute to future treatment options for MS.

For more information about the study, and to see if you may qualify,

Please email ResearchNCNE@neurocenterne.com / call 781-551-5812 opt.6